On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor ...

Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in ...

it's about as confident tone as you can expect from or as you'd want from a management team," said Kevin Gade, chief operating officer at Bahl & Gaynor, which owns Lilly's shares. Eli Lilly also ...

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

Tirzepatide will be available at pharmacies in Ireland initially in doses of 2.5 mg and 5 mg, with availability of higher ...

In a recent Tech Talk X webinar, we explored the broader implications and what comes next. OpenAI’s closed-model strategy, ...